KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 87 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $58,591 | +49.0% | 38,802 | -14.7% | 0.00% | – |
| Q4 2023 | $39,332 | -35.4% | 45,471 | 0.0% | 0.00% | – |
| Q3 2023 | $60,931 | -25.1% | 45,471 | 0.0% | 0.00% | – |
| Q2 2023 | $81,393 | -27.5% | 45,471 | +57.5% | 0.00% | – |
| Q1 2023 | $112,289 | +14.4% | 28,866 | 0.0% | 0.00% | – |
| Q4 2022 | $98,144 | -89.5% | 28,866 | -83.2% | 0.00% | -100.0% |
| Q3 2022 | $937,050 | +620.8% | 171,621 | +494.5% | 0.00% | – |
| Q2 2022 | $130,000 | -42.7% | 28,866 | -6.2% | 0.00% | – |
| Q1 2022 | $227,000 | +22.0% | 30,763 | +6.6% | 0.00% | – |
| Q4 2021 | $186,000 | +8.1% | 28,866 | -2.5% | 0.00% | – |
| Q3 2021 | $172,000 | -43.4% | 29,620 | +0.6% | 0.00% | -100.0% |
| Q2 2021 | $304,000 | -9.3% | 29,450 | -7.5% | 0.00% | 0.0% |
| Q1 2021 | $335,000 | -29.2% | 31,850 | +4.2% | 0.00% | 0.0% |
| Q4 2020 | $473,000 | +3.3% | 30,567 | -2.7% | 0.00% | 0.0% |
| Q3 2020 | $458,000 | -0.4% | 31,402 | +29.3% | 0.00% | 0.0% |
| Q2 2020 | $460,000 | -20.0% | 24,293 | -18.9% | 0.00% | -50.0% |
| Q1 2020 | $575,000 | +2.5% | 29,936 | +2.3% | 0.00% | +100.0% |
| Q4 2019 | $561,000 | +148.2% | 29,262 | +24.4% | 0.00% | – |
| Q3 2019 | $226,000 | +60.3% | 23,524 | 0.0% | 0.00% | – |
| Q2 2019 | $141,000 | +14.6% | 23,524 | +12.1% | 0.00% | – |
| Q1 2019 | $123,000 | -37.6% | 20,985 | 0.0% | 0.00% | – |
| Q4 2018 | $197,000 | -38.1% | 20,985 | +12.5% | 0.00% | -100.0% |
| Q3 2018 | $318,000 | +0.3% | 18,661 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $317,000 | +57.7% | 18,661 | +24.3% | 0.00% | – |
| Q1 2018 | $201,000 | +39.6% | 15,008 | 0.0% | 0.00% | – |
| Q4 2017 | $144,000 | -12.7% | 15,008 | 0.0% | 0.00% | – |
| Q3 2017 | $165,000 | +21.3% | 15,008 | 0.0% | 0.00% | – |
| Q2 2017 | $136,000 | 0.0% | 15,008 | +42.1% | 0.00% | – |
| Q1 2017 | $136,000 | +37.4% | 10,564 | 0.0% | 0.00% | – |
| Q4 2016 | $99,000 | -3.9% | 10,564 | 0.0% | 0.00% | – |
| Q3 2016 | $103,000 | +45.1% | 10,564 | 0.0% | 0.00% | – |
| Q2 2016 | $71,000 | -24.5% | 10,564 | 0.0% | 0.00% | – |
| Q1 2016 | $94,000 | -32.9% | 10,564 | 0.0% | 0.00% | – |
| Q4 2015 | $140,000 | +26.1% | 10,564 | 0.0% | 0.00% | – |
| Q3 2015 | $111,000 | -61.3% | 10,564 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $287,000 | +40.7% | 10,564 | +58.8% | 0.00% | – |
| Q1 2015 | $204,000 | -18.1% | 6,651 | 0.0% | 0.00% | -100.0% |
| Q4 2014 | $249,000 | +7.3% | 6,651 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $232,000 | -25.2% | 6,651 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $310,000 | – | 6,651 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |